Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.

PloS One
Jeffrey J WallinLori S Friedman

Abstract

The PTEN/PI3K pathway is commonly mutated in cancer and therefore represents an attractive target for therapeutic intervention. To investigate the primary phenotypes mediated by increased pathway signaling in a clean, patient-relevant context, an activating PIK3CA mutation (H1047R) was knocked-in to an endogenous allele of the MCF10A non-tumorigenic human breast epithelial cell line. Introduction of an endogenously mutated PIK3CA allele resulted in a marked epithelial-mesenchymal transition (EMT) and invasive phenotype, compared to isogenic wild-type cells. The invasive phenotype was linked to enhanced PIP(3) production via a S6K-IRS positive feedback mechanism. Moreover, potent and selective inhibitors of PI3K were highly effective in reversing this phenotype, which is optimally revealed in 3-dimensional cell culture. In contrast, inhibition of Akt or mTOR exacerbated the invasive phenotype. Our results suggest that invasion is a core phenotype mediated by increased PTEN/PI3K pathway activity and that therapeutic agents targeting different nodes of the PI3K pathway may have dramatic differences in their ability to reverse or promote cancer metastasis.

References

May 2, 2003·Nature Reviews. Cancer·Peter Friedl, Katarina Wolf
Oct 22, 2003·The Journal of Cell Biology·Jayanta DebnathJoan S Brugge
Mar 16, 2004·Science·Yardena SamuelsVictor E Velculescu
Oct 27, 2004·Apoptosis : an International Journal on Programmed Cell Death·M OsakiH Ito
Jan 14, 2005·Proceedings of the National Academy of Sciences of the United States of America·Sohye KangPeter K Vogt
Feb 3, 2005·Bioorganic & Medicinal Chemistry Letters·Zhijian ZhaoCraig W Lindsley
Dec 1, 2005·Breast Cancer Research and Treatment·Shao Ying LiBarry Iacopetta
Dec 3, 2005·Cancer Research·Steven J IsakoffJoan S Brugge
Dec 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert L YauchLukas C Amler
Dec 21, 2005·The Journal of Cell Biology·Hanna Y IrieJoan S Brugge
Feb 3, 2006·Cancer Research·Kathryn E O'ReillyNeal Rosen
Mar 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Hong LiuMina J Bissell
Oct 25, 2006·Molecular and Cellular Biology·Jung-Sik KimTodd Waldman
Mar 31, 2007·Nature Methods·Genee Y LeeMina J Bissell
Feb 19, 2008·Cancer Research·David SarrióJosé Palacios
May 8, 2008·Clinical & Experimental Metastasis·T BlickE W Thompson
Sep 17, 2008·Oncogene·L Zhao, P K Vogt
Dec 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Federica Di NicolantonioAlberto Bardelli
Feb 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·John P GustinBen Ho Park
Apr 18, 2009·Molecular Cancer Research : MCR·Xiaolan HuGuy Cavet
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evelyn YaoKlaus P Hoeflich
Jul 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Klaus P HoeflichMark R Lackner
Oct 15, 2009·Science Signaling·Dimitrios IliopoulosPhilip N Tsichlis
Jan 28, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephan E BaldusHelmut E Gabbert
Jul 8, 2010·Breast Cancer Research : BCR·Leonard Da SilvaSunil R Lakhani
Jul 14, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Siyuan Zhang, Dihua Yu

❮ Previous
Next ❯

Citations

Jan 1, 2012·African Journal of Traditional, Complementary, and Alternative Medicines : AJTCAM·Ying WangWenli Ma
Jan 30, 2016·Nature Reviews. Drug Discovery·Fabrizio MarcucciRuggero De Maria
Oct 16, 2015·BMC Cancer·Valeria SimoneFranco Silvestris
Jul 31, 2014·The Journal of Pathology·Wei ZhouKlaus P Hoeflich
Apr 11, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jie ChenDanfeng Xu
Aug 14, 2013·Proceedings of the National Academy of Sciences of the United States of America·Ariella B HankerCarlos L Arteaga
Apr 28, 2016·Oncotarget·Darío García-CarracedoJuana María García-Pedrero
Apr 16, 2019·Frontiers in Oncology·Fabrizio MarcucciCristiano Rumio
Feb 6, 2020·Biochemical Society Transactions·Ralitsa R Madsen
May 12, 2020·Frontiers in Molecular Biosciences·Sugandha BhatiaErik W Thompson
Jun 16, 2021·Nature Reviews. Drug Discovery·Bart VanhaesebroeckKlaus Okkenhaug
Nov 22, 2014·Journal of Medicinal Chemistry·Joachim RudolphWeiru Wang
Jan 18, 2014·Journal of Medicinal Chemistry·Steven T StabenKlaus P Hoeflich
Sep 12, 2020·Recent Patents on Anti-cancer Drug Discovery·Arunaksharan Narayanankutty

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE17785

Methods Mentioned

BETA
transgenic
genotyping
ELISA
Transfections
electrophoresis
transfection

Software Mentioned

ImageXpress

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Basement Membranes

Basement membranes are thin, specialized extracellular matrices surrounding most tissues in all metazoans. Here is the latest research on basement membranes.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.